Australia markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.49+0.03 (+0.46%)
At close: 04:00PM EST
6.49 0.00 (0.00%)
After hours: 05:39PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.47B
Enterprise value 1.24B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.36
Price/book (mrq)19.07
Enterprise value/revenue 9.74
Enterprise value/EBITDA -23.94

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 3-18.26%
S&P500 52-week change 322.74%
52-week high 310.88
52-week low 34.72
50-day moving average 36.48
200-day moving average 36.34

Share statistics

Avg vol (3-month) 34.06M
Avg vol (10-day) 32.31M
Shares outstanding 5220.11M
Implied shares outstanding 6N/A
Float 8171.11M
% held by insiders 10.41%
% held by institutions 183.65%
Shares short (30 Dec 2021) 413.02M
Short ratio (30 Dec 2021) 41.67
Short % of float (30 Dec 2021) 46.60%
Short % of shares outstanding (30 Dec 2021) 45.92%
Shares short (prior month 29 Nov 2021) 48.49M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin -55.41%
Operating margin (ttm)-42.33%

Management effectiveness

Return on assets (ttm)-12.40%
Return on equity (ttm)-413.68%

Income statement

Revenue (ttm)127.66M
Revenue per share (ttm)0.64
Quarterly revenue growth (yoy)-49.40%
Gross profit (ttm)17.71M
EBITDA -51.95M
Net income avi to common (ttm)-70.74M
Diluted EPS (ttm)-0.36
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)245.76M
Total cash per share (mrq)1.21
Total debt (mrq)19.4M
Total debt/equity (mrq)25.17
Current ratio (mrq)2.42
Book value per share (mrq)0.38

Cash flow statement

Operating cash flow (ttm)-115.01M
Levered free cash flow (ttm)-8.53M